Barclays analyst Matt Miksic maintains Insulet (NASDAQ:PODD) with a Equal-Weight and lowers the price target from $213 to $200.
Barclays Maintains Equal-Weight on Insulet, Lowers Price Target to $200
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.